micro-community-banner
 
  • Saved

1yr
Highlights from the American Society of Clinical Oncology Annual Meeting

The five-day meeting reflects advances in the diagnosis, treatment, and prevention of all types of cancer, including chronic lymphocytic leukemia, the most common type of leukemia, affecting more than 200,000 people in the United States today and with global incidence rising, according to ASCO.

  • Saved

1yr
Long-Term Survival for Lymphoid Neoplasms and National Health Expenditure (EUROCARE-6): a Retrospective, Population-Based Study

Long-Term Survival for Lymphoid Neoplasms and National Health Expenditure (EUROCARE-6): a Retrospective, Population-Based Study

Source : https://pubmed.ncbi.nlm.nih.gov/38703784/

Italian Ministry of Health, European Commission, Estonian Research Council.

Ten-year age-standardized relative survival rates for each lymphoid malignancy was higher in countries in the highest national health expenditure quartile than in countries in the lowest quartile, with a decreasing pattern through quartiles for many lymphoid malignancies.

  • Saved

1yr

Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: a Phase 1 Dose-Escalation Trial

Source : https://jamanetwork.com/journals/jamaoncology/fullarticle/2818572

Combination inotuzumab ozogamicin and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin is a safe, well tolerated, and clinically active chemoimmunotherapy regimen warranting further clinical investigation.

  • Saved

1yr
Immune Effector Cell-Associated Haematotoxicity After CAR T-Cell Therapy: From Mechanism to Management

Immune Effector Cell-Associated Haematotoxicity After CAR T-Cell Therapy: From Mechanism to Management

Source : https://pubmed.ncbi.nlm.nih.gov/38734026/

Genetically engineered chimeric antigen receptor (CAR) T cells have become an effective treatment option for several advanced B-cell malignancies. Haematological side-effects, classified in 2023 as immune effector cell-associated haematotoxicity (ICAHT),...

The EHA and EBMT consensus grading system provides a framework for severity-based best practice recommendations, similar to what already exists for CRS and ICANS.

  • Saved

1yr

Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma

Source : https://jamanetwork.com/journals/jamaoncology/fullarticle/2818571

Patients who did not receive bridging radiotherapy had a higher risk of disease progression despite having smaller tumor sizes and not requiring bridging systemic therapy.